HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kei Ohnuma Selected Research

Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)

2/2021CD26/Dipeptidyl Peptidase IV and Its Multiple Biological Functions.
1/2019Development of novel monoclonal antibodies with specific binding affinity for denatured human CD26 in formalin-fixed paraffin-embedded and decalcified specimens.
2/2014Establishment of monoclonal anti-human CD26 antibodies suitable for immunostaining of formalin-fixed tissue.
11/2013CD26 expression on T-anaplastic large cell lymphoma (ALCL) line Karpas 299 is associated with increased expression of versican and MT1-MMP and enhanced adhesion.
1/2013Nuclear localization of CD26 induced by a humanized monoclonal antibody inhibits tumor cell growth by modulating of POLR2A transcription.
2/2011Mechanisms of confluence-dependent expression of CD26 in colon cancer cell lines.
10/2010Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines.
1/2008The role of CD26/dipeptidyl peptidase IV in cancer.
3/2007CD26/dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune disorders.
3/2005Regulation of p38 phosphorylation and topoisomerase IIalpha expression in the B-cell lymphoma line Jiyoye by CD26/dipeptidyl peptidase IV is associated with enhanced in vitro and in vivo sensitivity to doxorubicin.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kei Ohnuma Research Topics

Disease

27Neoplasms (Cancer)
03/2021 - 05/2002
10Malignant Mesothelioma
01/2019 - 07/2007
4Immune System Diseases (Immune Disorders)
01/2019 - 03/2007
3Inflammation (Inflammations)
01/2019 - 04/2011
2Carcinogenesis
02/2021 - 03/2007
2Psoriasis (Pustulosis Palmaris et Plantaris)
11/2019 - 01/2019
2Neoplasm Metastasis (Metastasis)
01/2019 - 03/2007
2Myelodysplastic Syndromes (Myelodysplastic Syndrome)
02/2016 - 05/2002
2Bronchiolitis Obliterans Syndrome
01/2016 - 04/2015
2Bronchiolitis
01/2016 - 04/2015
2Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma)
11/2013 - 08/2005
2Type 2 Diabetes Mellitus (MODY)
10/2013 - 10/2010
2Graft vs Host Disease (Graft-Versus-Host Disease)
07/2013 - 02/2004
2Carcinoma (Carcinomatosis)
02/2011 - 06/2006
2Hypoxia (Hypoxemia)
06/2005 - 12/2003
1Diabetes Mellitus
02/2021
1Triple Negative Breast Neoplasms
01/2021
1Rheumatic Diseases (Rheumatism)
09/2019
1Erythema
01/2019
1Atherosclerosis
01/2018
1Pruritus (Itching)
06/2017
1Hypersensitivity (Allergy)
04/2017
1Edema (Dropsy)
02/2016
1Synovitis
02/2016
1Experimental Arthritis
07/2015
1Arthritis (Polyarthritis)
05/2015
1Fibrosis (Cirrhosis)
04/2015
1Insulin Resistance
03/2015
1Pleural Diseases
01/2014
1Infections
12/2013
1Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome)
07/2013
1Necrosis
02/2013
1Mesothelioma
03/2012
1Body Weight (Weight, Body)
04/2011
1Colonic Neoplasms (Colon Cancer)
02/2011
1Jaundice (Icterus)
11/2010
1Fever (Fevers)
11/2010

Drug/Important Bio-Agent (IBA)

15Monoclonal AntibodiesIBA
03/2021 - 06/2006
10Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA
02/2021 - 03/2005
5Dipeptidyl-Peptidase IV InhibitorsIBA
02/2021 - 10/2010
5Proteins (Proteins, Gene)FDA Link
02/2014 - 06/2005
4Membrane Glycoproteins (Membrane Glycoprotein)IBA
02/2021 - 06/2006
4Biological ProductsIBA
01/2019 - 12/2012
3Glycoproteins (Glycoprotein)IBA
01/2019 - 03/2005
3EnzymesIBA
06/2017 - 06/2009
3CollagenIBA
01/2016 - 02/2014
3Small Interfering RNA (siRNA)IBA
07/2007 - 08/2005
2Biomarkers (Surrogate Marker)IBA
03/2021 - 01/2014
2Imiquimod (Aldara)FDA LinkGeneric
11/2019 - 01/2019
2Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesIBA
01/2018 - 06/2009
2LipidsIBA
01/2016 - 02/2004
2p38 Mitogen-Activated Protein KinasesIBA
03/2007 - 08/2005
2Integrin beta1IBA
03/2007 - 08/2005
2AntigensIBA
01/2006 - 08/2005
1Hypoglycemic Agents (Hypoglycemics)IBA
02/2021
1Glucose (Dextrose)FDA LinkGeneric
02/2021
1ErbB Receptors (EGF Receptor)IBA
01/2021
1Tyrosine Kinase InhibitorsIBA
01/2021
1Therapeutic UsesIBA
11/2019
1Immune Checkpoint InhibitorsIBA
09/2019
1Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA
01/2019
1Fibroblast Growth Factors (Fibroblast Growth Factor)IBA
01/2019
1Ubiquitin-Specific ProteasesIBA
10/2018
13- (4- (4- (3- methyl- 1- phenyl- 1H- pyrazol- 5- yl)piperazin- 1- yl)pyrrolidin- 2- ylcarbonyl)thiazolidineIBA
01/2018
1Toll-Like Receptors (Toll-Like Receptor)IBA
01/2018
1LipopolysaccharidesIBA
01/2018
1Substance PIBA
06/2017
1Neurotransmitter Agents (Neurotransmitter)IBA
06/2017
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2016
1Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
01/2016
1RoxithromycinIBA
07/2015
1AdipokinesIBA
03/2015
1PeriostinIBA
05/2014
1Caveolin 1IBA
02/2014
1Adenosine DeaminaseIBA
02/2014
1Fibronectins (Fibronectin)IBA
02/2014
1Formaldehyde (Formol)FDA Link
02/2014
1ParaffinIBA
02/2014
1AsbestosIBA
01/2014
1IntegrinsIBA
01/2014
1Matrix Metalloproteinase 14 (MT1-MMP)IBA
11/2013
1Membrane Proteins (Integral Membrane Proteins)IBA
11/2013
1Versicans (Versican)IBA
11/2013
1Fas Ligand Protein (Fas Ligand)IBA
02/2013
1Granzymes (Granzyme)IBA
02/2013
1InterferonsIBA
02/2013
1LeptinIBA
04/2011
1Sitagliptin Phosphate (Januvia)FDA Link
04/2011
1Messenger RNA (mRNA)IBA
02/2011
1Transcription Factors (Transcription Factor)IBA
02/2011

Therapy/Procedure

15Therapeutics
03/2021 - 02/2007
3Transplantation
02/2016 - 05/2002
2Immunotherapy
09/2019 - 10/2010
2Drug Therapy (Chemotherapy)
03/2012 - 03/2007
1Immunomodulation
02/2021
1Premedication
04/2017
1Cell Transplantation
01/2016
1Bone Marrow Transplantation (Transplantation, Bone Marrow)
05/2015
1Hematopoietic Stem Cell Transplantation
04/2015
1Intraperitoneal Injections
07/2013